Medline (MDLN) Financials

Medline’s Q2 2026 results show strong revenue growth and improved operating cash flow, but profitability weakened substantially. The company’s revenue increased to $7.685 billion, up 11.6% from $6.886 billion in Q2 2025 and 4.5% from Q1 2026. Gross profit rose 16.8% year over year to $2.215 billion, lifting the gross margin to approximately 28.8% from 27.7%.

Despite the stronger top line, operating income declined to $395 million from $642 million in the year-ago quarter. The operating margin fell to about 5.1% from 9.3%, primarily because selling, general and administrative expenses increased to $1.295 billion and other operating expenses rose sharply to $348 million. Consolidated net income fell 58.3% year over year to $139 million, while net income attributable to common shareholders declined to $60 million, or $0.07 per diluted share.

Cash generation improved considerably. Q2 operating cash flow was $715 million, compared with $197 million in Q2 2025 and $412 million in Q1 2026. However, cash declined by $364 million during the quarter because of $461 million in investing outflows and $159 million in net financing outflows. The financing activity largely reflected debt refinancing, with $4.733 billion of debt issued and $4.774 billion repaid.

The balance sheet remains liquid but highly leveraged. Medline held $2.327 billion in cash and $350 million in short-term investments at the end of Q2. Total debt was approximately $12.577 billion, while total liabilities reached $20.273 billion. Goodwill and intangible assets totaled roughly $21.6 billion, or about 55% of total assets, making asset quality and future impairment risk important considerations for investors.

• Revenue growth remains robust: Q2 revenue rose 11.6% year over year, and first-half revenue was approximately 11.6% higher than in the first half of 2025.
• Gross margin improved: Q2 gross margin increased to approximately 28.8% from 27.7% in Q2 2025, indicating better gross-profit conversion despite higher revenue.
• Operating cash flow strengthened: Q2 operating cash flow increased to $715 million from $197 million a year earlier, providing meaningful liquidity for debt service and investment.
• Working-capital pressure eased sequentially: The cash-flow impact from operating assets and liabilities improved to negative $99 million in Q2 from negative $124 million in Q1.
• Liquidity is substantial: Cash, cash equivalents and short-term investments totaled approximately $2.677 billion at the end of Q2, while current assets exceeded current liabilities by more than four times.
• Debt refinancing dominated financing activity: Medline issued and repaid more than $4.7 billion of debt during Q2. This appears to be primarily refinancing rather than a major change in reported debt, but future interest costs and maturity terms remain important.
• Capital investment is continuing: Property, plant and equipment purchases totaled $111 million in Q2, up from $96 million in Q1, supporting capacity and infrastructure but consuming cash.
• Noncontrolling interests are significant: $79 million of Q2 net income was attributable to noncontrolling interests, leaving only $60 million for common shareholders. Investors should focus on earnings attributable to common equity rather than consolidated earnings alone.
• Operating profitability deteriorated: Q2 operating income fell 38.5% year over year, and the operating margin dropped to approximately 5.1% from 9.3%.
• Leverage and interest costs remain risks: Medline had approximately $12.6 billion of debt and paid $263 million of cash interest in Q2. In addition, goodwill and intangible assets represent more than half of total assets, increasing sensitivity to impairment or refinancing pressures.

Overall, Medline is producing attractive revenue growth and substantially better operating cash flow, but the earnings trend is less favorable. Investors should watch whether the company can control SG&A and other operating costs, stabilize operating margins, and convert its stronger cash flow into sustained debt reduction rather than relying on continued refinancing.